Comments
Loading...
Humacyte (NASDAQ:HUMA) Stock Quotes, Forecast and News Summary
Humacyte Stock (NASDAQ: HUMA) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Humacyte (HUMA) stock?
You can purchase shares of Humacyte (NASDAQ:HUMA) through any online brokerage.
Who are Humacyte (HUMA) competitors?
Other companies in Humacyte’s space includes: Tectonic Therapeutic (NASDAQ:TECX), KalVista Pharma (NASDAQ:KALV), Celcuity (NASDAQ:CELC), Upstream Bio (NASDAQ:UPB) and Altimmune (NASDAQ:ALT).
What is the forecast, or price target, for Humacyte (HUMA) stock?
Humacyte has a consensus price target of $13.56.
What is the current price for Humacyte (HUMA)?
The stock price for Humacyte (NASDAQ: HUMA) is $3.6882 last updated February 21, 2025 at 10:36 AM EST.
Does Humacyte (HUMA) pay a dividend?
There are no upcoming dividends for Humacyte.
When is Humacyte (NASDAQ:HUMA) reporting earnings?
Humacyte’s Q1 earnings are confirmed for Friday, May 9, 2025.
Is Humacyte (HUMA) going to split?
There is no upcoming split for Humacyte.
What sector and industry does Humacyte (HUMA) operate in?
Humacyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.